End Stage Renal Disease. Chronic kidney disease, stage 5
Conditions
Interventions
Intervention 1: Intervention group: The treatment group consists of 50 patients receiving 400 mg orally of Pentoxifylline daily for 3 months. Intervention 2: Control group consisted of 50 patients rec
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: CRP>1 Age over 18 years Initiate hemodialysis for at least 3 months and three times a week Ability to understand and sign a consent form Properly functioning arteriovenous fistula or catheter Dialysis adequacy above 1.2
Exclusion criteria
Exclusion criteria: Pregnancy The presence of any chronic,active,uncontrolled or severe chronic inflammatory disease(autoimmune disease,connective tissue disease,malignancy,HIV,liver disaese and pulmonary disease) The presence of chronic infection or the occurrence of acute infection in a recent month Hemoglobin is less than 10g/dL Concurrently presence in another trial(drug or supplement) A medical history(such as heart attack or brain injury)or sergical in the last 3 months Symptoms of malabsorption Bleeding disorders(Includes coagulopathies)or high risk of bleeding Change in diet in the last 1 month Abuse of alcohol and other substances that cause dependence
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum level of TNF-a. Timepoint: Before intervention. At the end of the intervention. Method of measurement: ELISA kit.;Serum level of CRP. Timepoint: Before intervention. At the end of the intervention. Method of measurement: ELISA kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: Before intervention. At the end of the intervention. Method of measurement: Standard questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAfshin Gharekhani
Tabriz University of Medical Sciences
Outcome results
None listed